Why the study?
How should low molecular weight heparins be dosed in patients with severe chronic kidney disease to minimize bleeding risk?
How should low molecular weight heparins be dosed in patients with severe chronic kidney disease to minimize bleeding risk?
This review evaluates preferred dosing strategies for LMWHs in patients with severe CKD to mitigate the increased risk of bleeding due to reduced renal clearance.
No takes yet. Share an insight, caveat, or question.
Caution advised dosing LMWHs in severe CKD; review leaves open optimal 2008 ACCP approach pending prospective trials.
Manny Saltiel (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: